We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -15.00 | -0.91% | 1,636.00 | 1,638.00 | 1,639.00 | 1,661.50 | 1,635.50 | 1,656.50 | 4,329,161 | 16:35:12 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.69 | 67.46B |
From Apr 2019 to Apr 2024
By Razak Musah Baba
LONDON--GlaxoSmithKline PLC (GSK.LN) said Friday that it has filed regulatory submissions in the U.S. and Europe, seeking approval for the drug Benlysta as a subcutaneous formulation type of injection for patients with systemic lupus disease.
Subcutaneous formulation is a form of injection whereby the drug is administered under the skin.
The pharmaceutical company said regulatory filings in other countries are planned during the course of 2016 and 2017. The subcutaneous formulation of Benlysta is currently not approved for use anywhere in the world.
Benlysta is indicated in the U.S. for the treatment of adult patients with active, autoantibody‑positive, systemic lupus erythematosus who are receiving standard therapy. It is licensed in the European Union as an add-on therapy in adult patients with active autoantibody-positive, with a high degree of disease activity, the company said.
At 0905 GMT, shares were up 3 pence, or 0.2%, at GBP16.52, valuing the company at GBP80.52 billion ($104.56 billion).
-Write to Razak Musah Baba at razak.baba@wsj.com; Twitter: @Raztweet
(END) Dow Jones Newswires
September 23, 2016 05:29 ET (09:29 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
